Select Page

Why the TAAR1 agonist ulotaront holds promise for schizophrenia

by | Nov 22, 2022

Why the TAAR1 agonist ulotaront holds promise for schizophrenia November 22, 2022 · By Brian Buntz · Drug Discovery & Development Ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical development, could prove to be a...

A novel phenotypic approach to CNS drug discovery

by | Nov 10, 2022

A novel phenotypic approach to CNS drug discovery November 10, 2022 · Drug Discovery World The newest addition to the free DDW podcast is the In Conversation With series, where DDW speaks with members of the drug discovery industry about their work and how it helps...

4 next-gen CNS drug development trends

by | Oct 24, 2022

4 next-gen CNS drug development trends By Brian Buntz · October 24, 2022 · Drug Discovery & Development The past couple of years have had a significant impact on CNS drug development, but it remains difficult to gauge how the field will evolve in the coming years....

Want to get in touch? Connect with the PsychoGenics research team.

Connect With Us
CONTACT

PsychoGenics Inc.
215 College Road, Paramus,
NJ 07652

Email: info@psychogenics.com
Phone: (914) 406-8019
Fax: (914) 406-8090

Copyright ©2024 PsychoGenics Inc. All rights reserved.